Tags

Type your tag names separated by a space and hit enter

Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy.
Menopause 2003 Nov-Dec; 10(6):534-7M

Abstract

OBJECTIVE

To assess the incidence of endometrial polyps during postmenopausal replacement therapy with tibolone, using an appropriate control group.

DESIGN

A total of 485 postmenopausal women were included in this open, prospective, comparative study for a duration of 36 months. Of this group, 249 women received 2.5 mg/day of tibolone and 244 women served as controls, receiving continuous-combined estrogen-progestogen therapy (HT). Transvaginal ultrasound, hysteroscopy, and directed biopsies were performed before treatment was initiated and at the end of the study.

RESULTS

Two hundred twenty-one of the women receiving tibolone and 203 receiving continuous-combined HT completed the study. Endometrial polyps were detected in 74 women (33.4%) from the tibolone group and in 22 women (10.8%) from the HT group (P < 0.01). The vaginal bleeding rate did not differ between the groups. The frequency of atrophic polyps was significantly higher in the tibolone group (P < 0.01). No difference was found in the size of the polyps.

CONCLUSIONS

Tibolone increases by threefold the risk for endometrial polyps.

Authors+Show Affiliations

Santa Cristina University Hospital, Universidad Autónoma de Madrid, Madrid, Spain. tperezm@meditex.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

14627862

Citation

Perez-Medina, Tirso, et al. "Tibolone and Risk of Endometrial Polyps: a Prospective, Comparative Study With Hormone Therapy." Menopause (New York, N.Y.), vol. 10, no. 6, 2003, pp. 534-7.
Perez-Medina T, Bajo-Arenas J, Haya J, et al. Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy. Menopause. 2003;10(6):534-7.
Perez-Medina, T., Bajo-Arenas, J., Haya, J., Sanfrutos, L., Iniesta, S., Bueno, B., & Castelo-Branco, C. (2003). Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy. Menopause (New York, N.Y.), 10(6), pp. 534-7.
Perez-Medina T, et al. Tibolone and Risk of Endometrial Polyps: a Prospective, Comparative Study With Hormone Therapy. Menopause. 2003;10(6):534-7. PubMed PMID: 14627862.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy. AU - Perez-Medina,Tirso, AU - Bajo-Arenas,José, AU - Haya,Javier, AU - Sanfrutos,Luis, AU - Iniesta,Silvia, AU - Bueno,Beatriz, AU - Castelo-Branco,Camil, PY - 2003/11/25/pubmed PY - 2004/5/11/medline PY - 2003/11/25/entrez SP - 534 EP - 7 JF - Menopause (New York, N.Y.) JO - Menopause VL - 10 IS - 6 N2 - OBJECTIVE: To assess the incidence of endometrial polyps during postmenopausal replacement therapy with tibolone, using an appropriate control group. DESIGN: A total of 485 postmenopausal women were included in this open, prospective, comparative study for a duration of 36 months. Of this group, 249 women received 2.5 mg/day of tibolone and 244 women served as controls, receiving continuous-combined estrogen-progestogen therapy (HT). Transvaginal ultrasound, hysteroscopy, and directed biopsies were performed before treatment was initiated and at the end of the study. RESULTS: Two hundred twenty-one of the women receiving tibolone and 203 receiving continuous-combined HT completed the study. Endometrial polyps were detected in 74 women (33.4%) from the tibolone group and in 22 women (10.8%) from the HT group (P < 0.01). The vaginal bleeding rate did not differ between the groups. The frequency of atrophic polyps was significantly higher in the tibolone group (P < 0.01). No difference was found in the size of the polyps. CONCLUSIONS: Tibolone increases by threefold the risk for endometrial polyps. SN - 1072-3714 UR - https://www.unboundmedicine.com/medline/citation/14627862/Tibolone_and_risk_of_endometrial_polyps:_a_prospective_comparative_study_with_hormone_therapy_ L2 - http://Insights.ovid.com/pubmed?pmid=14627862 DB - PRIME DP - Unbound Medicine ER -